In a prospective randomised cross-over study, we compared the effects of ACE inhibitor temocapril and calcium channel blocker (CCB) amlodipine on ambulatory blood pressure in 59 asymptomatic elderly hypertensive patients (mean age 69 years). This study was performed in a cross-over fashion after a 2-week placebo period and 4 to 8 weeks each of treatment with temocapril and amlodipine. Of those 59 hypertensive patients, three patients with side effects and 10 patients whose office BPs did not achieve the target BPs were excluded, and the remaining 46 were analysed in this study: they consisted of 30 dippers, with a night time reduction in systolic BP (SBP) у10% and 16 non-dippers, with reduction by Ͻ10%. At the baseline, there were no significant dif-
Introduction
In recent years, the usefulness of non-invasive ambulatory blood pressure monitoring (ABPM) as a method for evaluating diurnal blood pressure (BP) variations in addition to the BP level per se has been reported. Non-dippers 1 (blunted night time BP fall), in particular, have been reported to have greater hypertensive target organ damage [1] [2] [3] [4] [5] and poorer cardiovascular prognosis. 4 This indicates that controlling night time and morning BPs may be essential for antihypertensive treatment. 6 Even when office BPs are well controlled, it is uncertain whether the BPs are controlled all day in clinical practice. Using ABPM, we noted that office BPs were ferences in the office, 24-h or daytime BPs between the two groups (dippers and non-dippers). Though the office BPs and daytime BPs were successfully controlled to the same levels with both treatments and in both dipping groups, the antihypertensive effects were stronger with the CCB than with the ACE inhibitor in the night time and morning, especially in non-dippers. We conclude that even though office BPs were controlled successfully to almost the same levels, there is a possibility that these long-acting drugs have differential antihypertensive effects on night time and morning BPs among hypertensive patients with different night time BP dipping statuses.
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well controlled by a calcium channel blocker (CCB) or ACE inhibitor, and we assessed diurnal BP variation.
Long-acting CCBs and long-acting ACE inhibitors are most popular antihypertensive drugs in Japan, and are recommended for use once daily. However, there are few reports assessing the efficacy of these drugs throughout 24 h, and we do not know how long the drugs remain at a therapeutic level after administration or how potent these drugs are. And there are few reports comparing these drugs in terms of diurnal BP variations. 7 We conducted this study to evaluate the effects of temocapril (a long-acting ACE inhibitor), and amlodipine (a long-acting CCB) on 24-h ambulatory BP under successful office BP control.
Patients and methods

Study design
The study was a randomised prospective cross-over study. After a 2-week washout and run-in period, baseline ABPM was performed. The patients were then randomised to temocapril (2-8 mg) or amlodipine (2.5-10 mg) for 4 to 8 weeks, and a second ABPM was performed. Then the drug used for treatment was changed from temocapril to amlodipine or from amlodipine to temocapril, and 4 to 8 weeks later a third ABPM was performed. The dose was adjusted according to the BP response to achieve successful BP control. Successful BP control was defined as a reduction to Ͻ150/90 mm Hg systolic/diastolic BP (SBP/DBP) and if the BP was higher than 150/90 mm Hg after treatment, a reduction of у20/10 mm Hg was considered successful. Initially, all patients were treated with temocapril (2 to 4 mg) or amlodipine (2.5 to 5 mg) once daily. Then, the temocapril dose was increased by 2 mg or amlodipine by 2.5 mg or by 4 mg or 5 mg, respectively for 2 weeks up to twice the maximum reference dose recommended in Japan (ie, to 8 mg for temocapril and 10 mg for amlodipine). For patients in whom BP was not controlled successfully within 8 weeks, ABPM was carried out after 8 weeks of each therapy.
Patients
We studied 59 consecutive asymptomatic (never treated) elderly hypertensive outpatients, each of whom had visited our office more than three times during 14 to 28 days and showed a mean office SBP Ͼ150 mm Hg or mean office DBP Ͼ90 mm Hg on two or more occasions during this run-in period. We did not use a placebo. All patients were uncomplicated and ambulant. Exclusion criteria included possible diabetes mellitus (fasting glucose Ͼ100 mg/dl and/or haemoglobin A1c Ͼ6.2%), secondary or malignant hypertension, history of myocardial infarction, angina pectoris, stroke, transient ischaemic attack or other severe concomitant disease before the study. Secondary hypertension was ruled out based on history of hypertension, physical examination, blood and urine tests. When secondary hypertension was suspected, we performed additional tests, including hormonal profile. Of the 59 consecutive hypertensive patients enrolled in this study, three cases did not complete the protocol because of side effects (one case had general fatigue, one case had facial oedema due to temocapril, and one case developed weakness due to excessive lowering of BP during amlodipine therapy; the patient who developed general fatigue was a 58-year-old man receiving amlodipine (10 mg) therapy. His clinic BP was 124/66 mm Hg, and his baseline BP was 176/88 mm Hg. Because he wanted to quit the study, we excluded him. Ten patients did not achieve successful BP control with only temocapril, and were excluded. Finally, the data from 46 patients who achieved successful BP control were analysed. Thirty were classified as dippers (night time SBP fall у10%, considered normal diurnal BP variation) and 16 were classified as non-dippers (night time SBP fall Ͻ10%, considered abnormal diurnal BP variation). Written, informed consent was obtained from all subjects. This study was approved by the Research Ethics Committee, Department of Cardiology, Jichi Medical School, Japan.
Measurement of blood pressure and heart rate
Measurement of office SBPs and DBPs were made by a single physician with a standard mercury sphygmomanometer at each clinical visit, 24 ± 4 h after the previous intake of medication (ie, at trough). Pulse rate (PR) was measured by pulse palpation for 30 seconds immediately after the BP measurement. These measurement were made in the seated position after patients had rested in the seated position for 5 min. We used the left arm for measurements with an appropriate-sized cuff because the left arm is ordinarily used for ABPM measurements. Automatic ABPM with electric-powered cuff inflation (TM2421, A&D, Tokyo, Japan), which recorded BP and PR every 30 min for 24 h, was performed. The ABPM device was attached in the morning. The accuracy of this device was previously validated. 8 The ambulatory data used in the present study were obtained using the oscillometric method. Each subject recorded his or her own daily activities. Patients with documented disturbed sleep (frequent waking during sleep) were not included in the present study. The night time BP was defined as the mean BP for the interval from the time the patient went to bed until he or she awoke. The morning BP was defined as the mean BP during the first 2 h after waking (5 points), and daytime BP as the mean BP from waking until he or she went to bed. The night lowest BP was the mean BP of three consecutive measurements, including as the middle value the lowest BP recorded during the night. The night-day ratio of BP was calculated as the ratio of night time BP to daytime BP. The night time SBP fall was calculated using the formula (daytime SBP − night time SBP)/daytime SBP and was also expressed as a percentage.
Other measurements
The body mass index was calculated as weight (kg)/height (m) 2 . The left ventricular (LV) wall thickness and LV end diastolic and systolic diameters were measured with an ultrasonic echocardiograph (ALOKA, SSD500CV, Tokyo, Japan). LV mass index (LVMI) was calculated using the formula introduced by Devereux et al. 
Statistical considerations
The SAS statistical program (SAS Institute, Cary, NC, USA) was used to perform all statistical analyses. Student's t-test was used to compare the mean values between dippers and non-dippers. A twotailed paired t-test was used to compare the mean values before and after each drug therapy within the same subgroup (dippers or non-dippers). Pearson's correlation coefficients were calculated to test the relationships among baseline BPs and changes in daytime, night time and morning BPs after each drug therapy. The chi-squared test was applied to examine difference between the prevalence in the two groups. P Ͻ 0.05 was considered significant. Data are expressed as the mean (s.d.) or prevalence. Table 1 shows the characteristics of the 46 patients who achieved successful BP control as assessed by office BP. There were 30 dippers and 16 non-dippers. At the baseline, there was no difference in the office BP, 24-h BP, daytime BP or clinical characteristics between the two groups. Night time BP and LVMI were significantly higher in the non-dippers than in the dippers. Figure 1 shows the differences in BPs after antihypertensive therapy using temocapril and amlodipine in dippers and non-dippers. In both dipping groups, there were no significant differences in the office or Data are expressed as mean (s.d.) or prevalence. * P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.0001: non-dippers vs dippers.
Results
Patients
Office BP and ambulatory BP
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Figure 1
Differences between BP after amlodipine treatment and BP after temocapril treatment, evaluated for office BPs and ambulatory BPs of dippers (n = 30) and non-dippers (n = 16), are shown. SBP, systolic blood pressure; DBP, diastolic blood pressure. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001; ****P Ͻ 0.0001: amlodipine vs temocapril within each dipping group. † P Ͻ 0.05: Dippers vs non-dippers for each difference. Dotted bars: dippers, solid bars: non-dippers. daytime BP reduction between the amlodipine and temocapril therapy. However, 24-h BP, night time BP and morning BP were significantly lower with amlodipine therapy than with temocapril therapy. The differences of morning SBP, DBP and nightlowest SBP between temocapril and amlodipine therapy in non-dippers were significantly greater than those in dippers. This indicates a significant difference between amlodipine and temocapril with respect to BP reduction.
There were significant negative correlations between the baseline BP level and the degree of SBP changes following temocapril and amlodipine therapy in daytime SBP, night time SBP, and morning SBP (Figure 2 ). There were no significant differences in the relationships among baseline BP and BP changes in daytime SBP, night time SBP, or morning SBP between dippers and non-dippers. Even with successful treatment as assessed by the office BP, the 24-h BP profiles were still higher than the normal value described in the Joint National Committee VI (JNC VD). 10 Concerning daytime BP, the broken line shows the normal SBP of 135 mm Hg (daytime normal BP level described in JNC VI) after antihyperten- sive therapy. Fifteen (33%) of 46 subjects treated with temocapril and 17 (40%) of 46 patients treated with amlodipine were below this line. As for night time BP, the broken line shows normal SBP of 120 mm Hg (night time normal BP level described in JNC VI) after antihypertensive therapy; 17 of 46 (40%) patients treated with temocapril and 27 of 46 (59%) patients treated with amlodipine were below this line ( 2 = 4.43, P = 0.035). On the other hand, among patients with baseline SBP less than 120 mm Hg, there were only two patients treated with temocapril, and none treated with amlodipine, whose BP decreased more than 10 mm Hg. Regarding morning hypertension (defined as a morning SBP of 140 mm Hg or higher), 20 of 46 (43%) patients treated with temocapril did not reduce morning BP more than 10 mm Hg, and nine of 46 (20%) patients treated with amlodipine did not ( 2 = 5.04, P = 0.025).
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Discussion
We performed a prospective study of the effects of temocapril (a long-acting ACE inhibitor) and amlodipine (a CCB) on diurnal BP variation in uncomplicated hypertensive elderly patients. There are few reports comparing the effects of these drugs on diurnal BP under successful control of office BP. Our aim in this study was to clarify the changes in night time and morning BP levels during antihypertensive therapy using an ACE inhibitor and a CCB, under successful office BP control with each drug in hypertensive patients with different night time BP dipping statuses (dippers and non-dippers). We excluded from the analysis 10 cases that were not controlled by temocapril alone, even after using twice the maximum recommended dose (8 mg). The office and daytime BPs decreased to a similar degree after treatment with each drug in both dippers and non-dippers.
Several previous reports concluded that ACE inhibitors reduced ambulatory BP levels throughout a 24-h period while maintaining diurnal BP variation. 11 In this study, we confirmed this finding in dippers. However, the antihypertensive effects of temocapril did not persist for 24-h in non-dippers, ie, the reductions in night time BPs and morning BPs were smaller than those caused by amlodipine. The same phenomenon was observed in a report comparing amlodipine and lisinopril. 7 We suggest three possible explanations for this phenomenon. First, the plasma half-life of temocapril (14.5-21.5 h) is shorter than that of amlodipine (35-48 h). However, once-daily administration is recommended for temocapril, as for other long-acting ACE inhibitors. In fact, other ACE inhibitors with plasma half-lives shorter than that of temocapril have been shown to act for more than 24 h. 12 Although the plasma halflife of these drugs is not so long, their high affinity for tissue ACE makes it possible for the drug efficacy to persist. Second, the average effective dose of tem-
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ocapril was shown to be 17.5 mg in a previous report, and in a few people even a 40 mg dosage was used. 13 However, the recommended dose of temocapril in Japan is 4 mg, and we used a maximum dose of 8 mg. Therefore, an inadequate dose of temocapril was not the problem. Third, our study population lives in a small island and has a tendency to have high salt intake. Therefore, it is possible that the insufficient efficacy of temocapril for night time and morning BP in non-dippers was due not only to the characteristics of the drug, but also to the characteristics of our population.
Concerning excessive BP reduction, one previous report showed that an ACE inhibitor (enalapril) decreased normal BP further in white-coat hypertensive patients, while a CCB (nifedipine SR) did not decrease normal BP further in such patients.
14 On the other hand, under conditions of successful office BP control using temocapril, excessive night time BP reduction seems to be rare, as shown in our study by the fact that when baseline SBPs were less than 120 mm Hg, there were only two patients whose BP decreased more than 10 mm Hg in response to treatment with temocapril.
Several reports on ambulatory BP found that CCBs had powerful effects on night time and morning BP. 7, 14 In our study, amlodipine once daily in the morning reduced the BP level throughout the day and night in both dippers and non-dippers. In nondippers, night time and morning high BP were well reduced by amlodipine. In dippers, the amlodipine treatment reduced not only the daytime BP, but also significantly further reduced the lower baseline night time BP. However, the decrease in night time BP was possibly not harmful, because the post-treatment BP levels were not excessively low. When the baseline night time SBP was less than 120 mm Hg, no further reduction in night time BP was observed with amlodipine ( Figure 2 ). This finding is consistent with our previous finding that no further night time BP reduction was observed in extreme-dippers with marked falls in night time BP.
14 It remains unclear whether or not these different antihypertensive effects on ambulatory BPs between CCBs and ACE inhibitors contribute to the prognosis of hypertensive patients. Two recent trials disclosed that the degree of office BP control was equal or better with CCBs, but the rate of major cardiovascular complications was higher with CCBs than with ACE inhibitors, 15, 16 Further studies are required to clarify this issue.
In conclusion, a once-daily dose of a long-acting CCB can control ambulatory BP throughout a 24-h period in elderly uncomplicated hypertensive patients with different night time BP dipping statuses, depending on the baseline BP level. On the other hand, with a long-acting ACE inhibitor, the BP reductions in the night time BPs of both dippers and non-dippers, in addition to the morning BPs of nondippers, were less than the reductions with a CCB. These characteristic effects of ACE inhibitors and
CCBs on 24-h ambulatory BP in hypertensive patients with different night time BP dipping statuses should be considered, even in cases of successful control of office BPs. Further prospective studies will be required to clarify whether these differences in antihypertensive effects affect the cardiovascular prognosis of dippers and non-dippers.
